Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
about
Role of ROS and RNS Sources in Physiological and Pathological ConditionsExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseAntidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting DrugDenervation does not Induce Muscle Atrophy Through Oxidative StressAlpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T MutantGlucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation.Polydatin Protects Bone Marrow Stem Cells against Oxidative Injury: Involvement of Nrf 2/ARE Pathways.Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.Phytanic Acid-Induced Neurotoxicological Manifestations and Apoptosis Ameliorated by Mitochondria-Mediated Actions of Melatonin.Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease.Blockade of RAGE ameliorates elastase-induced emphysema development and progression via RAGE-DAMP signaling.Age-dependent alterations to paraventricular nucleus insulin-like growth factor 1 receptor as a possible link between sympathoexcitation and inflammation.Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement.The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders.AGEs and neurodegeneration: the Nrf2/glyoxalase-1 interaction.Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.Tetramethylpyrazine Ameliorates Rotenone-Induced Parkinson's Disease in Rats: Involvement of Its Anti-Inflammatory and Anti-Apoptotic Actions.Type-I interferons in Parkinson's disease: innate inflammatory response drives fate of neurons in model of degenerative brain disorder: An editorial comment on 'Type-I interferons mediate the neuroinflammatory response and neurotoxicity induced by rAn adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.Neuroprotective Effects of Sulphated Agaran from Marine Alga Gracilaria cornea in Rat 6-Hydroxydopamine Parkinson's Disease Model: Behavioural, Neurochemical and Transcriptional Alterations.Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.Tackling dipeptidyl peptidase IV in neurological disorders.The effects of rotenone-induced toxicity via the NF-κB-iNOS pathway in rat liver.N-methyl-N-nitrosourea induces retinal degeneration in the rat via the inhibition of NF-κB activation.Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease.Time to get Personal: A Framework for Personalized Targeting of Oxidative Stress in Neurotoxicity and Neurodegenerative Disease
P2860
Q26740342-B7BAB3B3-81C7-40BF-AAD6-A470C8BC455BQ26801173-0BA098BC-E600-4B7E-866B-11DBD2020B6FQ27301094-975745DC-706F-49D2-A198-C31BD582DB1DQ33564256-67D68B33-FB3D-422F-8B1C-62F5A6E1B45BQ36131340-6F7D4CF6-7FD3-4C91-A191-30124B6A17B3Q36183922-98393DDE-35B5-458C-9515-8E6B4FDF38E7Q36339320-5120A357-8496-406C-BF6D-45A44DC48242Q36386720-5CCF4E27-EB68-493F-ADD5-D4C9C7D6D9ABQ38713935-EC9890A4-F3F9-4D41-AE27-4183EC22A222Q38736369-33B2CCD1-D1BE-4B24-8D99-2E22D3A2D929Q38862845-E730AAF9-A358-4C3D-8ACC-47FE6AED5B86Q38985841-8C7DAD29-16E2-4C2B-9B00-3241FB22A63AQ39391880-43DAD27F-7AB1-4FC3-A6D4-F5416252A6E8Q41010767-23AB0C94-C6D7-41C4-BE8D-DB67E4F3840CQ41661210-ADCB5471-C218-4D3F-96E4-F8C15C2FC262Q42316275-404DC976-34AE-4FE1-A3E2-DEFFE5B96A0DQ45201060-DA45EB08-EA42-4AD6-8F69-41CAEFE0199CQ46871693-A65C6850-4049-4AF0-B5DD-02856776A75DQ48089290-D65BF6FD-07BE-49E8-A338-7B21AC0FBC9FQ48171351-BCE9EC79-066A-412D-9C59-749905B02799Q48521515-68D0AB89-17B6-41C2-AE87-7130DDB65FCFQ48886971-0895097B-CCEA-4B43-A1EF-0D2505E8FE60Q49940117-1BBB1422-9B8E-45BD-96BB-FA56CF37108AQ50940606-30A1E6FC-78B5-45DD-A805-F26C5529C623Q51318819-A070B5DE-4BE6-4D2A-B814-634C840D7A33Q55190915-2966B850-7B1F-4972-AA14-1143761DB90BQ55226753-88CAC7AC-EBA5-4902-8F1E-5743286EC3CDQ57148215-1913D7C0-86BD-4546-A812-610563A00E5F
P2860
Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Neuroprotective effects of vil ...... ntioxidant signaling pathways.
@en
Neuroprotective effects of vil ...... ntioxidant signaling pathways.
@nl
type
label
Neuroprotective effects of vil ...... ntioxidant signaling pathways.
@en
Neuroprotective effects of vil ...... ntioxidant signaling pathways.
@nl
prefLabel
Neuroprotective effects of vil ...... ntioxidant signaling pathways.
@en
Neuroprotective effects of vil ...... ntioxidant signaling pathways.
@nl
P2860
P356
P1476
Neuroprotective effects of vil ...... antioxidant signaling pathways
@en
P2093
Marwa M Safar
P2860
P304
P356
10.1111/JNC.13087
P407
P577
2015-03-26T00:00:00Z